K
Krystal Biotech, Inc. (KRYS)
245.39
0.00 (0.00%)
Get all premium features to the best stock analysis tool
245.39
0.00 (0.00%)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Name | Position |
|---|---|
| Dr. David Chien M.D. | Senior Vice President of Clinical Development |
| Dr. Stephane Paquette Ph.D. | Senior Vice President of Corporate Development |
| Mr. John Karakkal | Vice President of North American Sales & Marketing |
| Mr. John Thomas | EVP, General Counsel & Corporate Secretary |
| Mr. Josh Suskin | Senior Director & Head of US Human Resources |
| Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO |
| Mr. Laurent Goux | EVP & GM of Europe |
| Date | Type | Document |
|---|---|---|
| 2026-01-12 | 8-K | krys-20260111.htm |
| 2026-01-08 | 8-K | krys-20260108.htm |
| 2025-12-23 | 8-K | krys-20251223.htm |
| 2025-11-03 | 10-Q | krys-20250930.htm |
| 2025-10-22 | 8-K | krys-20251022.htm |
| 2025-08-04 | 10-Q | krys-20250630.htm |
| 2025-07-25 | 8-K | krys-20250725.htm |
| 2025-07-24 | 8-K | krys-20250724.htm |
| 2025-07-09 | 8-K | krys-20250709.htm |
| 2025-06-02 | 8-K | krys-20250602.htm |
| Ms. Christine Wilson |
| Senior VP & Head of US Commercial |
| Ms. Kathryn A. Romano CPA | Executive VP & Chief Accounting Officer |
| Ms. Suma M. Krishnan | Founder, President of R&D and Director |